` MXC (MGC Pharmaceuticals Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

MXC
vs
S
S&P/ASX 300

Over the past 12 months, MXC has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +6% growth.

Stocks Performance
MXC vs S&P/ASX 300

Loading
MXC
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
MXC vs S&P/ASX 300

Loading
MXC
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
MXC vs S&P/ASX 300

Loading
MXC
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
MGC Pharmaceuticals Ltd vs Peers

S&P/ASX 300
MXC
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

MGC Pharmaceuticals Ltd
Glance View

Market Cap
18.2m AUD
Industry
Pharmaceuticals

MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. The firm is primarily focused on producing standardized, phytocannabinoid and plant-derived medicines. The Company’s Nature to Medicine strategy comprises the entire supply chain, from botanical research, to develop new strains of Cannabis Sativa, preclinical and clinical research, product manufacturing, distribution, as well as the development of drug delivery systems. The Group has also completed a Phase II double-blind, randomized, placebo controlled clinical trial in Israel and India, to evaluate the safety and efficacy of a natural anti-inflammatory based formulation ArtemiC on patients diagnosed with Corona Virus Disease 2019 (COVID-19).

MXC Intrinsic Value
Not Available
Back to Top